IP Library Granted Patent US 10,238,673
Granted Patent B2
US 10,238,673 · App. 15/667,095 · Granted Mar 26, 2019

Methods and compositions for treatment of dry eye and correction of organ dysfunctions

Inventor: Diana Driscoll (Roanoke, TX)
Assignee: GENETIC DISEASE INVESTIGATORS, LLC
A61K31/685A61K9/0048A61K31/14A61K31/221A61K31/465A61K31/4748A61K31/51A61K33/06A61K45/06A61K9/0014A61K9/0031A61K9/0034A61K31/205A61P27/00A61P27/02
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,238,673
App. No.
15/667,095
Granted
Mar 26, 2019
Kind
B2
Abstract

The present invention includes compositions and methods for treating certain conditions such as dry eye or dry mouth with a comprising a choline compound; a cholinesterase inhibitor; and Acetyl-L-Carnitine, wherein the composition is provided in an amount sufficient to treat dry eye or dry mouth.

Claims (45)

1. A method of treating dry eye in a subject in need thereof comprising administering to the subject an effective an oral composition comprising a choline compound; a cholinesterase inhibitor and Acetyl-L-Carnitine sufficient to treat dry eye.

2. The method of claim 1 , wherein the dry eye comprise keratoconjunctivitis sicca, aqueous tear deficiency (ATD), allergies, Sjogren's syndrome, vitamin A deficiency, blepharitis, meibomian gland disease, allergic conjunctivitis, pterygium, ocular symptoms of graft versus host disease, ocular allergy, atopic keratoconjunctivitis, vernal keratoconjunctivitis, uveitis, anterior uveitis, Behcet's disease, Steven Johnson syndrome, ocular cicatricial pemphigoid, chronic ocular surface inflammation caused by viral infection, herpes simplex keratitis, ocular rosacea, pinguecula, or dry eye associated with refractive surgery.

3. The method of claim 1 , wherein the composition improves at least one of:

Tear break-up time (TBUT) (tear film break-up time), corneal staining, or Ocular Surface Disease Index (OSDI).

4. The method of claim 1 , further comprising adding one or more pharmaceutically acceptable excipients.

5. The method of claim 1 , wherein the composition comprises:

a choline compound selected from at least one of choline at 100 mg to 1,000 mg, lecithin at 100 mg to 3 grams, or L-alpha glycerylphosphorylcholine at 30 mg to 2,400 mg;

75 mcg to 300 mcg of the cholinesterase inhibitor is huperzine A; and

50 mg to 600 mg of Acetyl-L-Carnitine.

6. The method of claim 1 , wherein the composition further comprises at least one of Thiamin or Magnesium.

7. The method of claim 1 , wherein the composition comprises per dose:

a choline compound selected from at least one of choline at 100 mg to 1,000 mg, lecithin at 100 mg to 3 grams, or L-alpha glycerylphosphorylcholine at 30 mg to 2,400 mg;

75 mcg of huperzine A;

150 mg of Acetyl-L-Carnitine; and

optionally 30 mg Thiamin and 30 mg Magnesium.

8. The method of claim 1 , wherein the range per dose is 30, 40, 50, 60, 70, 80, 90, 100, 150, 200, 250, 270, 300, 350, 400, 450, 500, 540, 600, 700, 750, 800, 900, 1,000, 1,100, 1,200, 1,300, 1,400, 1,500, 1,600, 1,700, 1,800, 1,900, 2,000, 2,100, 2,200, 2,300, 2,400, 2,500, 2,600, 2,700, 2,800, 2,900, 3,000, 30 to 2,400, 40 to 2,300, 50 to 2,000, 60 to 1,500, 70 to 1,000, 80 to 750, 90 to 2,400, 200 to 2,300, 300 to 2,200, 400 to 2,100, 500 to 2,000, 600 to 1,900, 700 to 1,800, 800 to 1,700, 900 to 1,600, 1,000 to 1,500, 1,100 to 1,400, 1,200 to 1,300, of the choline compound.

9. The method of claim 1 , wherein the range per dose is 75, 80, 90, 100, 125, 150, 175, 200, 225, 250, 275, 300, 75 to 300, 80 to 275, 90 to 250, 100 to 225, 125 to 200, 150 to 175 mcg of huperzine A.

10. The method of claim 1 , wherein the range per dose is 50, 75, 80, 90, 100, 125, 150, 175, 200, 225, 250, 275, 300, 325, 350, 375, 400, 425, 450, 475, 500, 525, 550, 575, 600, 50 to 600, 75 to 600, 80 to 575, 90 to 550, 100 to 525, 125 to 500, 150 to 475, 175 to 450, 200 to 425, 225 to 400, 250 to 375, 275 to 350, 300 to 325 Acetyl-L-Carnitine.

11. The method of claim 6 , wherein the range per dose is 10, 20, 30, 40, 50, 60 mg Thiamin.

12. The method of claim 6 , wherein the range per dose is 0.3, 0.5, 0.75, 1.0, 5, 10, 15, 20, 25, 30, 40, 50, 60, 70, 80, 90, 100 mg Magnesium.

13. A method of treating dry eye or xerostomia, comprising:

identifying a subject having at least one of dry eye or xerostomia; and

providing the patient with a medical composition adapted for oral administration that comprises:

a choline compound selected from at least one of choline at 100 mg to 1,000 mg, lecithin at 100 mg to 3 grams, or L-alpha glycerylphosphorylcholine at 30 mg to 2,400 mg;

75 mcg-300 mcg of huperzine A;

50 mg to 600 mg of Acetyl-L-Carnitine; and

10-180 mg Thiamin or Magnesium.

14. The method of claim 13 , wherein the dry eyes comprise keratoconjunctivitis sicca, aqueous tear deficiency (ATD), allergies, Sjogren's syndrome, vitamin A deficiency, blepharitis, meibomian gland disease, allergic conjunctivitis, pterygium, ocular symptoms of graft versus host disease, ocular allergy, atopic keratoconjunctivitis, vernal keratoconjunctivitis, uveitis, anterior uveitis, Behcet's disease, Steven Johnson syndrome, ocular cicatricial pemphigoid, chronic ocular surface inflammation caused by viral infection, herpes simplex keratitis, ocular rosacea, pinguecula, or dry eye associated with refractive surgery.

15. The method of claim 13 , wherein the composition improves at least one of:

Tear break-up time (TBUT) (tear film break-up time), corneal staining, or Ocular Surface Disease Index (OSDI).

16. The method of claim 13 , wherein the composition further comprises one or more pharmaceutically acceptable excipients.

17. The method of claim 13 , wherein the composition comprises:

a choline compound selected from at least one of choline at 100 mg to 1,000 mg, lecithin at 100 mg to 3 grams, or L-alpha glycerylphosphorylcholine at 30 mg to 2,400 mg;

75 mcg to 300 mcg of the cholinesterase inhibitor is huperzine A; and

50 mg to 600 mg of Acetyl-L-Carnitine.

18. The method of claim 13 , wherein the composition comprises per dose:

a choline compound selected from at least one of choline at 100 mg to 1,000 mg, lecithin at 100 mg to 3 grams, or L-alpha glycerylphosphorylcholine at 30 mg to 2,400 mg;

75 mcg of huperzine A;

150 mg of Acetyl-L-Carnitine; and

optionally 30 mg Thiamin and 30 mg Magnesium.

19. The method of claim 13 , wherein the range per dose is 30, 40, 50, 60, 70, 80, 90, 100, 150, 200, 250, 270, 300, 350, 400, 450, 500, 540, 600, 700, 750, 800, 900, 1,000, 1,100, 1,200, 1,300, 1,400, 1,500, 1,600, 1,700, 1,800, 1,900, 2,000, 2,100, 2,200, 2,300, 2,400, 2,500, 2,600, 2,700, 2,800, 2,900, 3,000, 30 to 2,400, 40 to 2,300, 50 to 2,000, 60 to 1,500, 70 to 1,000, 80 to 750, 90 to 2,400, 200 to 2,300, 300 to 2,200, 400 to 2,100, 500 to 2,000, 600 to 1,900, 700 to 1,800, 800 to 1,700, 900 to 1,600, 1,000 to 1,500, 1,100 to 1,400, 1,200 to 1,300, of the choline compound.

20. The method of claim 13 , wherein the range per dose is 75, 80, 90, 100, 125, 150, 175, 200, 225, 250, 275, 300, 75 to 300, 80 to 275, 90 to 250, 100 to 225, 125 to 200, 150 to 175 mcg of huperzine A.

21. The method of claim 13 , wherein the range per dose is 50, 75, 80, 90, 100, 125, 150, 175, 200, 225, 250, 275, 300, 325, 350, 375, 400, 425, 450, 475, 500, 525, 550, 575, 600, 50 to 600, 75 to 600, 80 to 575, 90 to 550, 100 to 525, 125 to 500, 150 to 475, 175 to 450, 200 to 425, 225 to 400, 250 to 375, 275 to 350, 300 to 325 Acetyl-L-Carnitine.

22. The method of claim 13 , wherein the range per dose is 10, 20, 30, 40, 50, 60 mg Thiamin.

23. The method of claim 13 , wherein the range per dose is 0.3, 0.5, 0.75, 1.0, 5, 10, 15, 20, 25, 30, 40, 50, 60, 70, 80, 90, 100 mg Magnesium.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 2, 2017
From: DRISCOLL, DIANA
To: GENETIC DISEASE INVESTIGATORS, LLC
Reel/Frame 043173/0168 →
Continuity (6)
Continuation In Part 15050612 · Feb 23, 2016
Continuation 14209717 · Mar 13, 2014
Provisional Application 61900697 · Nov 6, 2013
Provisional Application 61856938 · Jul 22, 2013
Provisional Application 61779131 · Mar 13, 2013
Related Publication 20170326163A1 · Nov 16, 2017